Best of ASCO - 2014 Annual Meeting

 

Welcome

Triple-Negative

Breast Cancer—Metastatic

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A multicentered randomized phase II comparison of single-agent carboplatin versus the combination of carboplatin and everolimus for the treatment of advanced triple-negative breast cancer.

Jami Aya Fukui

TPS1109

A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC).

Amy Jo Chien

1072

A phase II clinical trial of pembrolizumab and selective androgen receptor modulator GTx-024 in patients with advanced androgen receptor-positive triple-negative breast cancer.

Jin Sun Lee-Bitar

1069

A phase II trial of olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer.

Zahi Ibrahim Mitri

TPS1111

A randomized phase II study of nab-paclitaxel + durvalumab + neoantigen vaccine versus nab-paclitaxel + durvalumab in metastatic triple-negative breast cancer (mTNBC).

Leonel Fernando Hernandez-Aya

TPS1114

AL101 mediated tumor inhibition in notch-altered TNBC PDX models.

Esther Channah Broner

1064

Association of SOX9 expression with sensitivity to CDK7 inhibition and overall survival in triple-negative breast cancer.

Xiaoxiang Guan

1065

Brain metastasis in patients with hereditary BRCA-mutated invasive breast cancer.

Haven Garber

1074

CENP-U function on TNBC.

Jin Zhang

e12546

Chronobiological assessment of triple-negative breast cancer.

Pati Revazishvili

e12564

Dora: A randomized phase II multicenter maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum responsive advanced triple-negative breast cancer (aTNBC).

Sarah Sammons

TPS1113

Effect of metformin on PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 expression in triple-negative breast cancer.

Ye Han

1063

Effect of RNA-binding protein MSI2 deficiency on progression in triple-negative breast cancer via stabilizing TP53INP1.

Ping Wei

e12555

Effector T-cell cytolytic activity modules derived from CD3+ single cells from human primary triple-negative breast cancer (TNBC) in multiple solid tumors to predict response to immune checkpoint blockade therapy (ICB).

Chaitanya Ramanuj Acharya

1073

Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in patients with advanced triple-negative breast cancer.

Jieqiong Liu

1066

Efficacy of platinum-based regimens as the first-line therapy in Chinese patients with advanced TNBC and deleterious BRCA1/2 mutations.

Nan Wang

e12565

High-throughput screening (HTS) of natural products with triple-negative breast cancer (TNBC) organoids.

Zhijian Sun

e12558

Immunohistochemical evaluation of Cyclin D1 and β-Catenin expression in subtypes of triple-negative breast cancer.

Tatiana N. Gudtskova

e12553

Immunotherapy predictive biomarkers in metastatic breast cancer (MBC).

Jeffrey S. Ross

1023

IMpassion130: Expanded safety analysis from a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)-naïve, locally advanced or metastatic triple-negative breast cancer (mTNBC).

Andreas Schneeweiss

1068

IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).

Peter Schmid

1003

Innate and adaptive immunotherapy: An orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T-cell therapy in patients with third line or greater TNBC.

Chaitali Singh Nangia

e12566

Ki-67 and Cyclin D1 in subtypes of triple-negative breast cancer with different androgen profiles.

Larisa N. Vashchenko

e12552

Learning from every patient: Real-world clinical outcomes of patients with metastatic triple-negative breast cancer treated in the community oncology setting.

Anchit Khanna

e12554

Longitudinal treatment patterns and adverse events (AEs) in younger patients (Pts) with metastatic triple-negative breast cancer (mTNBC): A real-world landscape analysis.

Nicole Maria Kuderer

e12562

MYC as a therapeutic target for the treatment of triple-negative breast cancer.

Sarah A. Foley

e12550

New docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer.

Michel Demeule

e12556

Outcomes of talazoparib (TALA) versus physician's choice of chemotherapy (PCT) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA (gBRCA) mutation by line of chemotherapy (CT) in the EMBRACA trial.

Johannes Ettl

1071

Patient-reported outcomes (PROs) from the phase III IMpassion130 trial of atezolizumab (atezo) plus nabpaclitaxel (nP) in metastatic triple-negative breast cancer (mTNBC).

Sylvia Adams

1067

Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC).

David B. Page

1015

Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).

Adam Brufsky

1013

Randomized, optimal dose-finding, phase II study of tri-weekly nab-paclitaxel in patients with metastatic breast cancer (ABROAD).

Fumikata Hara

1070

Real-world data regarding the efficacy of neoadjuvant carboplatin-paclitaxel followed by dose-dense adriamycin-cyclophosphamide for triple-negative early breast cancer.

Ajay Ashok Bhojwani

e12559

Searching for a link between Ki-67 values and HER2 absence in 297 patients with triple-negative breast cancer.

Sven Kurbel

e12551

SGNLVA-002: Single-arm, open label phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer.

Hyo S. Han

TPS1110

Somatic mutations in triple-negative breast carcinoma and high-grade serous ovarian carcinoma from young women.

Pedro Adolpho MP Serio

e12561

Targeting serum response factor as a novel therapeutic approach for triple-negative breast cancer.

Maria Prencipe

e12560

The role of miR200c in leptin-mediated triple-negative breast cancer progression to an epithelial-to-mesenchymal transition.

Lucas Wang

e12548

Triple-negative (TNBC) metastatic breast cancer (MBC) patients (pts): Is chemotherapy (CHT) choice influenced by adjuvant (adj) treatments? Results from the GIM-13 AMBRA study.

Giorgio Mustacchi

e12549

VIOLETTE: A randomized phase II study to assess the DNA damage response inhibitors AZD6738 or AZD1775 in combination with olaparib (Ola) versus Ola monotherapy in patients (pts) with metastatic, triple-negative breast cancer (TNBC).

Andrew Tutt

TPS1112